drugset
drugset / Trial / NCT06138613

Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness

NCT06138613 ↗

Phase 3 Active not recruiting 705 enrolled Vanda Pharmaceuticals
RandomizedParallel-groupOpen-labelTreatment

Summary

An open label study to investigate the safety and efficacy of tradipitant in participants affected by motion sickness during travel

Timeline

Start
2023-02-27
Primary completion
2027-09-30
Completion
2027-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Tradipitant Small molecule — Oral

Indications

motion sickness